CTMX
CytomX Therapeutics Inc
2.70$
-1.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 670.8% | 514.9% | 484.6% | 147.4% | 0.0% | – | – | 8.4% | 11.0% | 2.1% | 1.3% | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 557.5% | 367.7% | 364.0% | 128.8% | 174.6% | 228.9% | 165.0% | 164.1% | 210.0% | 76.7% | 60.4% | 90.2% | |
| 128.8% | 162.8% | 132.1% | 35.7% | 56.3% | 64.0% | 52.7% | 56.3% | 80.6% | 29.7% | 21.5% | 39.2% | |
| 686.3% | 530.5% | 496.1% | 164.6% | 230.9% | 292.9% | 217.7% | 220.4% | 290.6% | 106.4% | 81.9% | 129.3% | |
| -586.3% | -430.5% | -396.1% | -64.6% | -130.9% | -192.9% | -117.7% | -120.4% | -190.6% | -6.4% | 18.1% | -29.3% | |
| 9.6% | 22.5% | 11.2% | 0.0% | 0.0% | 18.8% | 2.6% | 0.2% | 3.8% | – | – | – | |
| -596.8% | -458.6% | -391.7% | -60.9% | -118.1% | -178.6% | -74.4% | -120.2% | -186.8% | 3.3% | 23.2% | -22.5% | |
| 0.2% | 0.1% | -0.1% | -0.7% | 24.0% | -0.7% | 20.3% | -4.3% | -3.8% | 3.8% | 0.2% | 0.3% | |
| -597.0% | -458.7% | -391.5% | -60.2% | -142.2% | -177.8% | -94.7% | -115.9% | -183.0% | -0.6% | 23.1% | -22.8% | |
| -571.8% | -420.5% | -384.6% | -58.6% | -127.7% | -188.4% | -113.9% | -116.5% | -186.0% | 5.4% | 24.5% | -20.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.